{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:15Z","timestamp":1794270135057,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107945","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:45:15Z","timestamp":1785307515000},"page":"107945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenomic variability in adolescents and youth with virologic rebound while receiving injectable cabotegravir\/rilpivirine: A multi-case series"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9622-6327","authenticated-orcid":false,"given":"Timothy J.","family":"Howze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-9017","authenticated-orcid":false,"given":"Nehali D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107945_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf120","article-title":"Long-acting injectable human immunodeficiency virus therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy","volume":"81","author":"Hastie","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/QAD.0000000000003085","article-title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy","volume":"36","author":"Mills","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0003","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0004","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/v17091254","article-title":"Real-world experience with long-acting injectable cabotegravir\/rilpivirine in HIV patients with unsuppressed viral load","volume":"17","author":"Trizzino","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf600","article-title":"Discontinuation of long-acting injectable cabotegravir\u2013rilpivirine in a large clinic cohort","volume":"12","author":"Christopoulos","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-pharmtox-021320-111248","article-title":"Pharmacogenomics of antiretroviral drug metabolism and transport","volume":"61","author":"Yu","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0008","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/pgs.11.160","article-title":"Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV\/AIDS treatment","volume":"13","author":"Li","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations\u2014implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0010","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/pgs.09.53","article-title":"Pharmacogenomics of CYP3A: considerations for HIV treatment","volume":"10","author":"Lakhman","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAI.0b013e3181bf648a","article-title":"CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1\u2013infected children receiving highly active antiretroviral therapy","volume":"54","author":"Saitoh","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0013","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2B6 and efavirenz-containing antiretroviral therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74506-x","article-title":"Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis","volume":"10","author":"Yoon","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-019-0217-3","article-title":"HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study","volume":"16","author":"Mounzer","year":"2019","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2016.72","article-title":"Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?","volume":"17","author":"Bielinski","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179364","article-title":"Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States","volume":"14","author":"Lemke","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060913","article-title":"Pharmacogenomics in solid tumors: a comprehensive review of genetic variability and its clinical implications","volume":"17","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0019","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/138920011795495321","article-title":"Clinically relevant genetic variations in drug metabolizing enzymes","volume":"12","author":"Pinto","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/jpm9030040","article-title":"Pharmacogenomic testing: clinical evidence and implementation challenges","volume":"9","author":"Hippman","year":"2019","journal-title":"J Pers Med"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0021","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv. Accessed July 9, 2026."},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetics and drug\u2013drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00899-16","article-title":"Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals","volume":"61","author":"Aouri","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0024","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkr087","article-title":"Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals","volume":"66","author":"Schipani","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0025","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0b013e3283593602","article-title":"Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine","volume":"26","author":"Frasco","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/v17111417","article-title":"Efficacy and safety of cabotegravir\u2013rilpivirine in PLWH: a real-world study","volume":"17","author":"Conti","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/hiv.70057","article-title":"Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: a systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV","volume":"26","author":"Ring","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2026.107945_bib0028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir plus rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:37:45Z","timestamp":1794267465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926002323"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107945","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomic variability in adolescents and youth with virologic rebound while receiving injectable cabotegravir\/rilpivirine: A multi-case series","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107945"}}